<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01257828</url>
  </required_header>
  <id_info>
    <org_study_id>SPN-10-001</org_study_id>
    <nct_id>NCT01257828</nct_id>
  </id_info>
  <brief_title>Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)</brief_title>
  <acronym>CSM-Protect</acronym>
  <official_title>Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AOSpine North America Research Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AOSpine North America Research Network</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CSM (Cervical spondylotic myelopathy) is the most common cause of spinal cord injury&#xD;
      worldwide. While there is evidence from the recently completed SpineNet prospective study&#xD;
      that surgical decompression is an effective treatment for CSM, it is clear that many patients&#xD;
      have remaining neurological impairment. While surgery is relatively safe, approximately 3% of&#xD;
      patients maintain a neurological problem. Given this background and data from preclinical&#xD;
      models of non-traumatic and traumatic spinal cord injury, there is strong evidence to&#xD;
      consider the potential benefit of adding a neuroprotective drug which aids in the treatment&#xD;
      of patients with CSM whom are undergoing surgical decompression. Riluzole is FDA-approved for&#xD;
      the treatment of amyotrophic lateral sclerosis, which has some similar clinical features to&#xD;
      CSM. Riluzole is currently under investigation for traumatic spinal cord injury. Given this&#xD;
      background, there is a strong basis to consider studying the potential neurological benefits&#xD;
      of Riluzole as a treatment to surgical decompression in patients with CSM.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">December 15, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Japanese Orthopedic Association Score (mJOA)</measure>
    <time_frame>Before the surgery, 180 days</time_frame>
    <description>The mJOA is a clinician administered scale. It evaluates four clinical dimensions; motor dysfunction score for upper and lower extremities, sensation loss and sphincter dysfunction. The total score ranges from 0 (worst) to 18 (best).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Nurick Score</measure>
    <time_frame>Pre-surgical, 180 days</time_frame>
    <description>Nurick score is a simple measure of neurological dysfunction and ranges from 0 (best) to 6 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36v2.0</measure>
    <time_frame>Before the surgery, 180 days</time_frame>
    <description>The SF36v2.0 is a health-related quality of life instrument that evaluates health status accross eight health dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neck Disability Index (NDI)</measure>
    <time_frame>Before the surgery, 180 days</time_frame>
    <description>The NDI evaluates patient self-reported functional outcomes related to neck conditions. The NDI score ranges from 0 (best) to 100 (worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cervical Pain Numeric Rating Scale</measure>
    <time_frame>Before the surgery, 180 days</time_frame>
    <description>Simple numeric rating scale with choises of answers from 0 (no pain) to 10 (worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>Before the surgery, 180 days</time_frame>
    <description>EQ-5D™ is a standardised instrument for use as a measure of health outcome. It provides a simple descriptive profile and a single index value for health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Spinal Injury Association Score (ASIA)</measure>
    <time_frame>Before the surgery, 180 days</time_frame>
    <description>The ASIA impairment scale describes a person's functional impairment as a result of their spinal cord injury.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Cervical Spondylotic Myelopathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo medication and decompressive cervical spine surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Riluzole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Riluzole in dose 50mg BID for 14 days prior to surgery and 28 days after the decompressive spine surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>riluzole</intervention_name>
    <description>50mg BID orally for 14 days prior to surgery and 28 days after the surgery</description>
    <arm_group_label>Riluzole</arm_group_label>
    <other_name>Rilutek</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo medication</intervention_name>
    <description>50mg BID orally for 14 days prior to surgery and 28 days after the surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 and 80 years&#xD;
&#xD;
          -  Diagnosis of symptomatic cervical spondylotic myelopathy defined as a combination of:&#xD;
&#xD;
               1. one or more of the following symptoms:&#xD;
&#xD;
                    -  Numb hands&#xD;
&#xD;
                    -  Clumsy hands&#xD;
&#xD;
                    -  Impairment of gait&#xD;
&#xD;
                    -  Bilateral arm paresthesiae&#xD;
&#xD;
                    -  l'Hermitte's phenomena&#xD;
&#xD;
                    -  Weakness And,&#xD;
&#xD;
               2. one or more of the following signs:&#xD;
&#xD;
                    -  Corticospinal distribution motor deficits&#xD;
&#xD;
                    -  Atrophy of hand intrinsic muscles&#xD;
&#xD;
                    -  Hyperreflexia&#xD;
&#xD;
                    -  Positive Hoffman sign&#xD;
&#xD;
                    -  Upgoing plantar responses&#xD;
&#xD;
                    -  Lower limb spasticity&#xD;
&#xD;
                    -  Broad based, unstable gait And,&#xD;
&#xD;
               3. MRI evidence of cervical spondylotic myelopathy&#xD;
&#xD;
          -  Scheduled for an elective surgery for cervical spondylotic myelopathy&#xD;
&#xD;
          -  Preoperative mJOA score ≥8 and ≤14&#xD;
&#xD;
          -  Women of child bearing potential must be:&#xD;
&#xD;
               -  Postmenopausal defined as amenorrhea for at least 2 years.&#xD;
&#xD;
               -  Surgically sterile, (have had a hysterectomy or bilateral oophorectomy, tubal&#xD;
                  ligation, or otherwise be incapable of pregnancy)&#xD;
&#xD;
               -  Abstinent (at the discretion of the investigator)&#xD;
&#xD;
               -  Having other congenital or medical condition that prevents subject from becoming&#xD;
                  pregnant&#xD;
&#xD;
               -  If sexually active, be practicing an effective method of birth control such as&#xD;
                  hormonal prescription oral contraceptives, progesterone implants or injections,&#xD;
                  intrauterine device (IUD), or male partner with a vasectomy. A double-barrier&#xD;
                  method such as condoms, diaphragms or cervical caps with spermicidal foam, cream&#xD;
                  or gel may be used as a birth control method.&#xD;
&#xD;
               -  Women of childbearing potential must have a negative serum β-human chorionic&#xD;
                  gonadotropin (β-hCG) pregnancy test or a negative urine pregnancy test at&#xD;
                  screening before the first dose of study drug is received.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous surgery for CSM&#xD;
&#xD;
          -  Concomitant symptomatic lumbar stenosis&#xD;
&#xD;
          -  CSM symptoms due to cervical trauma (at the discretion of the investigator)&#xD;
&#xD;
          -  Hypersensitivity to riluzole or any of its components&#xD;
&#xD;
          -  Neutropenia measured as absolute neutrophil count (ANC) measured in cells per&#xD;
             microliter of blood of &lt; 1500 at screening visit&#xD;
&#xD;
          -  Creatinine level of &gt; 1.2 milligrams (mg) per deciliter (dl) in males or &gt; 1.1&#xD;
             milligrams per deciliter in females at screening visit Liver enzymes (ALT or AST) 3x&#xD;
             higher than normal values at screening visit.&#xD;
&#xD;
          -  Liver enzymes (ALT or AST) 3x higher than normal values at screening visit.&#xD;
&#xD;
          -  Subject will be using any of the following medications which are classified as CYP1A2&#xD;
             inhibitors or inducers*during the course of the drug regimen:&#xD;
&#xD;
        Inhibitors:&#xD;
&#xD;
          -  Ciprofloxacin&#xD;
&#xD;
          -  Enoxacin&#xD;
&#xD;
          -  Fluvoxamine&#xD;
&#xD;
          -  Methoxsalen&#xD;
&#xD;
          -  Mexiletine&#xD;
&#xD;
          -  Oral contraceptives&#xD;
&#xD;
          -  Phenylpropanolamine&#xD;
&#xD;
          -  Thiabendazole&#xD;
&#xD;
          -  Zileuton&#xD;
&#xD;
        Inducers:&#xD;
&#xD;
          -  Montelukast&#xD;
&#xD;
          -  Phenytoin&#xD;
&#xD;
             *Note: no washout period required; if these medications are discontinued, subjects are&#xD;
             eligible to be enrolled in the trial.&#xD;
&#xD;
          -  Systemic infection such as AIDS, HIV, and active hepatitis&#xD;
&#xD;
          -  Active malignancy defined as history of invasive malignancy, except if the patient has&#xD;
             received treatment and displayed no clinical signs and symptoms for at least five&#xD;
             years&#xD;
&#xD;
          -  Recent history (less than 3 years) of chemical substance dependency or significant&#xD;
             psychosocial disturbance that may impact the outcome or study participation&#xD;
&#xD;
          -  Breastfeeding at screening visit and plan to continue during the course of the study&#xD;
             drug&#xD;
&#xD;
          -  Unlikely to comply with the follow-up evaluation schedule&#xD;
&#xD;
          -  Unlikely to comply with investigational drug regime&#xD;
&#xD;
          -  Participation in a clinical trial of another investigational drug or device within the&#xD;
             past 30 days&#xD;
&#xD;
          -  Is a prisoner&#xD;
&#xD;
          -  Unable to converse, read or write English at elementary school level&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Fehlings, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Branko Kopjar, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Spine Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University Orthopaedics</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rothman Institute Orthopaedics</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harborview Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N-2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Toronto Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre</name>
      <address>
        <city>Montral</city>
        <state>Quebec</state>
        <zip>H3H 2L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Saskatchewan, Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Fehlings MG, Wilson JR, Karadimas SK, Arnold PM, Kopjar B. Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial. Spine (Phila Pa 1976). 2013 Oct 15;38(22 Suppl 1):S68-75. doi: 10.1097/BRS.0b013e3182a7e9b0. Review.</citation>
    <PMID>23962993</PMID>
  </reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>October 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2010</study_first_posted>
  <last_update_submitted>November 1, 2018</last_update_submitted>
  <last_update_submitted_qc>November 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Diseases</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riluzole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

